Our observation of the opposite effects of simvastatin and pravastatin on glucose-stimulated insulin secretion is in agreement with previous reports showing that simvastatin, but not pravastatin, was associated with an increased risk of incident diabetes [1]. This evidence concerns the gene INS and diabetes mellitus.